{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:25:41Z","timestamp":1786955141697,"version":"build-2736575974"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    Somatic mutations and copy number alterations of the adenine-thymine (AT)-rich interactive domain-containing protein 1A (\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    ), a tumor suppressor gene, are associated with poor prognosis in many cancers, including adult hepatocellular carcinomas (HCC). In this study, ARID1A protein expression, clinicopathologic features, and outcomes were investigated in 59 pediatric malignant hepatocellular tumors (2004 to 2022) relative to\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    mutation and copy number status. Additional studies were performed on the impact of the loss of ARID1A protein expression on genomic instability, immune-cell infiltration, and PD-L1 protein expression. Twenty-three of the 59 (38.9%) children with malignant hepatocellular tumors (age: 0.4 to 13.8\u00a0y, M:F=2:1) harbored\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    alterations (mutations and\/or copy number alterations). Nine tumors (15.2%) with biallelic alterations (\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    \u2212\/\u2212) showed higher metastasis at presentation (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.01), were frequently CHIC high-risk (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.05), had aggressive histology (HCN-NOS and HCC) (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.002), and were negative for ARID1A immunohistochemistry (IHC) (100%). ARID1A loss by IHC was 100% sensitive and 98% specific, with 90% positive and 100% negative predictive value for\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    \u2212\/\u2212 tumors. ARID1A-negative tumors showed higher chromosomal instability (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.04), immune infiltrates (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.005), and PD-L1 expression by IHC (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.05). Patients with both ARID1A-negative and ARID1A-negative\/PD-L1-positive tumors showed the lowest disease-specific survival in the intermediate and high CHIC-risk and all PRETEXT subgroups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =ns\n                    <jats:italic toggle=\"yes\">)<\/jats:italic>\n                    . The association of biallelic\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    alterations with high-risk features and poor outcomes identifies\n                    <jats:italic toggle=\"yes\">ARID1A<\/jats:italic>\n                    as a potential new biomarker in the risk stratification of children with malignant hepatocellular tumors. ARID1A IHC is a reliable tool to identify these aggressive tumors. Associated PD-L1 expression may offer new therapeutic options via checkpoint inhibitors.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002578","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:00:25Z","timestamp":1781596825000},"page":"1106-1119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Biallelic ARID1A Alterations"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-5386","authenticated-orcid":false,"given":"Kalyani R.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Urbicain","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Sarabia","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia R.","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Major","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin E.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angshumoy","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Askin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Heczey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology and Oncology, Seattle Children\u2019s Hospital, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Pediatric Surgical Oncology Laboratory, Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev A.","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Pediatric Surgical Oncology Laboratory, Department of Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Sumazin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology and Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores H.","family":"Lopez-Terrada","sequence":"additional","affiliation":[{"name":"Department of Pathology at Baylor College of Medicine and Texas Children\u2019s Hospital, Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-05-1225","article-title":"The p270 (ARID1A\/SMARCF1) subunit of mammalian SWI\/SNF-related complexes is essential for normal cell cycle arrest","volume":"65","author":"Nagl","year":"2005","journal-title":"Cancer Res"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"eadh4435","DOI":"10.1126\/sciadv.adh4435","article-title":"Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations","volume":"10","author":"D\u2019Ambrosio","year":"2024","journal-title":"Sci Adv"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.21633","article-title":"Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types","volume":"33","author":"Jones","year":"2012","journal-title":"Hum Mutat"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/ng.2256","article-title":"Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma","volume":"44","author":"Guichard","year":"2012","journal-title":"Nat Genet"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/hep.15.16","article-title":"Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice","volume":"2","author":"Schulze","year":"2015","journal-title":"Hepat Oncol"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12957-021-02202-9","article-title":"Identification and validation of a five-gene prognostic signature for hepatocellular carcinoma","volume":"19","author":"Yang","year":"2021","journal-title":"World J Surg Oncol"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.18632\/aging.202586","article-title":"Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma","volume":"13","author":"Zhao","year":"2021","journal-title":"Aging"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-015-0164-3","article-title":"Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma","volume":"34","author":"He","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"e14307","DOI":"10.1016\/j.heliyon.2023.e14307","article-title":"The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma","volume":"9","author":"Meng","year":"2023","journal-title":"Heliyon"},{"key":"R11-20260817","first-page":"3163955","article-title":"ARID1A is a prognostic biomarker and associated with immune infiltrates in hepatocellular carcinoma","volume":"2022","author":"Feng","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cells9092002","article-title":"Low ARID1A expression is associated with poor prognosis in hepatocellular carcinoma","volume":"9","author":"Yim","year":"2020","journal-title":"Cells"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep4.1659","article-title":"ARID1A deficiency is associated with high programmed death ligand 1 expression in hepatocellular carcinoma","volume":"5","author":"Iseda","year":"2021","journal-title":"Hepatol Commun"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","article-title":"Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer","volume":"11","author":"Hirsch","year":"2021","journal-title":"Cancer Discov"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41467-021-25430-9","article-title":"Genetic and epigenetic basis of hepatoblastoma diversity","volume":"12","author":"Nagae","year":"2021","journal-title":"Nat Commun"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"e27745","DOI":"10.1002\/pbc.27745","article-title":"Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation","volume":"66","author":"Haines","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2022.04.035","article-title":"Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults","volume":"77","author":"Sumazin","year":"2022","journal-title":"J Hepatol"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/10668969211042638","article-title":"Pediatric metastatic hepatoblastoma with an ARID1A mutation and rhabdoid cells","volume":"30","author":"Alturkustani","year":"2022","journal-title":"Int J Surg Pathol"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/gim.2015.47","article-title":"A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer","volume":"18","author":"Sukhai","year":"2016","journal-title":"Genet Med"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.29262","article-title":"Molecular classification of hepatoblastoma and prognostic value of the HB 16-gene signature","volume":"66","author":"Buendia","year":"2017","journal-title":"Hepatology"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","article-title":"Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads","volume":"25","author":"Ye","year":"2009","journal-title":"Bioinformatics"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dnarep.2019.03.007","article-title":"SWI\/SNF: complex complexes in genome stability and cancer","volume":"77","author":"Ribeiro-Silva","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.29672","article-title":"New insights into diagnosis and therapeutic options for proliferative hepatoblastoma","volume":"68","author":"Hooks","year":"2018","journal-title":"Hepatology"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"pkz007","DOI":"10.1093\/jncics\/pkz007","article-title":"Trends in international incidence of pediatric cancers in children under 5 years of age: 1988-2012","volume":"3","author":"Hubbard","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"R28-20260817","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/pbc.24219","article-title":"Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies","volume":"59","author":"Trobaugh-Lotrario","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R29-20260817","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3748\/wjg.v24.i35.3980","article-title":"Pediatric hepatocellular carcinoma","volume":"24","author":"Khanna","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R30-20260817","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","article-title":"ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity","volume":"187","author":"Maxwell","year":"2024","journal-title":"Cell"},{"key":"R31-20260817","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/diagnostics12030592","article-title":"Relevance of ARID1A mutations in endometrial carcinomas","volume":"12","author":"De Leo","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R32-20260817","doi-asserted-by":"crossref","first-page":"155063","DOI":"10.1016\/j.prp.2023.155063","article-title":"Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma","volume":"255","author":"Hwang","year":"2024","journal-title":"Pathol Res Pract"},{"key":"R33-20260817","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"R34-20260817","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cjp2.103","article-title":"Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers","volume":"4","author":"Khalique","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"R35-20260817","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2017.10.028","article-title":"Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma","volume":"68","author":"Hu","year":"2018","journal-title":"J Hepatol"},{"key":"R36-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-021-00995-8","article-title":"Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial","volume":"14","author":"Hong","year":"2022","journal-title":"Genome Med"},{"key":"R37-20260817","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12935-019-0738-9","article-title":"Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis","volume":"19","author":"Liu","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R38-20260817","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.31206","article-title":"Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation","volume":"72","author":"Itoh","year":"2020","journal-title":"Hepatology"},{"key":"R39-20260817","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"R40-20260817","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41416-018-0144-4","article-title":"Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma","volume":"119","author":"Liu","year":"2018","journal-title":"Br J Cancer"},{"key":"R41-20260817","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13062-024-00452-7","article-title":"PLAU promotes growth and attenuates cisplatin chemosensitivity in ARID1A-depleted non-small cell lung cancer through interaction with TM4SF1","volume":"19","author":"Zheng","year":"2024","journal-title":"Biol Direct"},{"key":"R42-20260817","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cas.16052","article-title":"ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance","volume":"115","author":"Huang","year":"2024","journal-title":"Cancer Sci"},{"key":"R43-20260817","doi-asserted-by":"crossref","first-page":"904031","DOI":"10.3389\/fonc.2022.904031","article-title":"Effect of CRISPR knockout of AXIN1 or ARID1A on proliferation and migration of porcine hepatocellular carcinoma","volume":"12","author":"Elkhadragy","year":"2022","journal-title":"Front Oncol"},{"key":"R44-20260817","doi-asserted-by":"crossref","first-page":"e2148013","DOI":"10.1001\/jamanetworkopen.2021.48013","article-title":"Independent assessment of the Children\u2019s Hepatic Tumors International Collaboration risk stratification for hepatoblastoma and the association of tumor histological characteristics with prognosis","volume":"5","author":"Zhou","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R45-20260817","doi-asserted-by":"crossref","first-page":"104694","DOI":"10.1016\/j.ejmg.2022.104694","article-title":"Recommending revised hepatoblastoma surveillance in children with a pathogenic ARID1A variant. Reply to \u201cCancer in ARID1A-Coffin-Siris syndrome: review and report of a child with hepatoblastoma\u201d by Carcamo et al","volume":"66","author":"van der Sluijs","year":"2023","journal-title":"2022 Eur J Med Genet"},{"key":"R46-20260817","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4143\/crt.2021.265","article-title":"Children\u2019s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system for pediatric patients with hepatoblastoma: a retrospective, hospital-based cohort study in South Korea","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat"},{"key":"R47-20260817","doi-asserted-by":"crossref","first-page":"552079","DOI":"10.3389\/fonc.2020.552079","article-title":"CHIC risk stratification system for predicting the survival of children with hepatoblastoma: data from children with hepatoblastoma in China","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:00:25Z","timestamp":1786953625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002578"}},"subtitle":["A Promising Novel Biomarker for Risk Stratification and Management in Pediatric Malignant Hepatocellular Tumors"],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002578","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2026-03-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}